NeurAxon, Inc. to Present at Upcoming Investor and Business Development Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will participate in the following conferences:

  • The Sachs 10th Annual Biotech in Europe Investor Forum, September 29 - 30, 2010 at the Radisson Blu Hotel in Zurich, Switzerland. Dr. Bloch will be part of the CNS & Neurology panel session on Wednesday, September 29th at 5:30 pm (local time) and will present a corporate overview on Thursday, September 30th at 11:45 am (local time).
  • The BIO Investor Forum, October 5 - 6, 2010 at the Palace Hotel in San Francisco. Dr. Bloch will present a corporate overview on Tuesday, October 5th at 2:30 pm (local time).

These presentations will provide an overview of NeurAxon and its portfolio of internally generated, novel, proprietary pain therapeutics including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in Phase 2 development for the treatment of acute migraine.

About NeurAxon, Inc.

NeurAxon, Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.



CONTACT:

MacDougall Biomedical Communications
Chris Erdman, 508-647-0209 x14

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.